drugset
drugset / Trial / NCT05517837

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

NCT05517837 ↗

Phase 0 Terminated 46 enrolled Bristol-Myers Squibb
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986421 in healthy adult participants.

Timeline

Start
2022-09-13
Primary completion
2023-07-14
Completion
2023-07-14

Outcome

Outcome not reported

Stopped: “Adverse change in the risk/benefit.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986421 Unknown — —

Indications

No indication recorded.